Navigation Links
Pharmaburst(R) 500: Optimized, Evolutionary ODT Performance
Date:8/11/2009

WILMINGTON, Del., Aug. 11 /PRNewswire/ -- SPI Pharma, Inc., a leader in oral dispersible tablet (ODT) technologies with its patented Pharmaburst(R) and Pharmafreeze(TM) platforms, recently announced the launch of Pharmaburst(R) 500. Using proprietary technology with superior organoleptics, Pharmaburst(R) 500 will most certainly raise the bar in terms of performance and economics that formulators have come to expect from a quick-dissolve dosage form.

Studies show that Pharmaburst(R) 500 outperforms all of its direct competitors with respect to product functionality and organoleptics. It is easy to use, cost-effective and readily formulated with various actives to make robust orally disintegrating tablets (ODTs). The finished ODT can be manufactured internally rather than through outsourcing.

Pharmaburst(R) was the first off-the-shelf, patented, co-processed ODT excipient system introduced in the pharmaceutical market. It is still the only ODT excipient system included in the US FDA's Inactive Ingredient Guide (IIG). It is now being used in a wide variety of new and generic drug applications around the world by many leading multinationals and several top generic companies.

Oral dispersible drugs containing Pharmaburst(R) have been successfully launched in regulated and developing markets around the world for indications such as migraine, allergy, analgesics, anxiety, oncology, schizophrenia, depression, and Parkinson's.

For more information, please visit www.spipharma.com.


'/>"/>
SOURCE SPI Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue
2. ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384
3. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)
4. AMG Launches EVOS fl, an 'Evolutionary' Fluorescence Microscope Based on Innovative EVOS Platform
5. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
6. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
7. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
8. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
9. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
10. Worlds Top 20 Pharmaceutical Companies Deploy Revolutionary H-Cube(R) From ThalesNano Inc.
11. Berkley Life Sciences Introduces LS Prime: A Revolutionary New Primary Liability Policy for the Life Science Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
Breaking Biology News(10 mins):